skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Candesartan cilexetil in the treatment of chronic heart failure

Review

(2956) Views  (752) Full article downloads

Authors: Jean-Philippe Baguet, Gilles Barone-Rochette, Yannick Neuder

Published Date March 2009 Volume 2009:5 Pages 257 - 264
DOI: http://dx.doi.org/10.2147/VHRM.S4650

Jean-Philippe Baguet, Gilles Barone-Rochette, Yannick Neuder

Department of Cardiology, University Hospital, 38043 Grenoble, France

Abstract: The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of course that they are not contraindicated. However, angiotensin II receptor blockers (ARBs) can also be a beneficial treatment option. Candesartan is a particular ARB, characterized by a strong binding affinity to the angiotensin II type 1 receptor and slow dissociation. The benefits of candesartan have been demonstrated by the CHARM programme, which showed that candesartan significantly reduces the incidence of cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function, when added to standard therapies or as an alternative to ACE inhibitors when these are poorly tolerated. Furthermore, candesartan can protect against myocardial infarction, atrial fibrillation and diabetes. Tolerance to candesartan is good, but blood pressure and serum potassium and creatinine levels must be monitored.

Keywords: chronic heart failure, angiotensin II receptor blockers, candesartan, left ventricular systolic function






 

Other articles by Professor Jean-Philippe Baguet



Readers of this article also read:

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study
Amlodipine and valsartan as components of a rational and effective fixed-dose combination
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Cardiac risk stratification: Role of the coronary calcium score
Role of olmesartan in combination therapy in blood pressure control and vascular function
Differential clinical profile of candesartan compared to other angiotensin receptor blockers
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University